Global $64.95 Bn Antidiabetic Drug Markets, 2021-2026 by Drug Type, Diabetic Type, Patient, Geography, Competitive Analysis – ResearchAndMarkets.com

Global $64.95 Bn Antidiabetic Drug Markets, 2021-2026 by Drug Type, Diabetic Type, Patient, Geography, Competitive Analysis – ResearchAndMarkets.com




Global $64.95 Bn Antidiabetic Drug Markets, 2021-2026 by Drug Type, Diabetic Type, Patient, Geography, Competitive Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Antidiabetic Drug Market (2021-2026) by Drug Type, Diabetic Type, Patient, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.

The Global Antidiabetic Drug Market is estimated to be USD 38.20 Bn in 2021 and is expected to reach USD 64.95 Bn by 2026, growing at a CAGR of 11.2%.

Market Dynamics

The major factors such as Unhealthy food habits among individuals of all ages, increase in the prevalence of diabetes (both type I and type II), increase in obesity among people are driving the rise of the anti-diabetic drug market. Furthermore, the rising elderly population is a major driver of market expansion.

According to the International Diabetes Foundation, diabetes affects one in every five persons aged 65 and up throughout the world. In addition, growing government spending and health-awareness efforts to successfully treat diabetes, as well as investments in research and development and the invention of different techniques to control diabetes and create sophisticated anti-diabetic drugs, as per the growing requirement is expected to create opportunities for the market growth.

However, an important factor restraining the antidiabetics drug market is the decrease in treatment and drug efficacy over time, which can lead to various health issues. In addition, the high cost of medicines is seen as a challenge for the growth of the global antidiabetic drug market.

Market Segmentation

  • By Drug Type, the market is classified into A-Glucosidase Inhibitors (Acarbose), Biguanides (Metformin), Dipeptidyl Peptidase IV (DPP-IV) Inhibitors (Sitagliptin), Meglitinides (Repaglinide), Sulfonylureas (Glimepiride), Thiazolidinediones (Pioglitazone), and others. Amongst all, the A-Glucosidase Inhibitors (Acarbose), segment is estimated to hold the highest market share during the forecast period.
  • By Diabetic Type, the market is classified as diabetes type 1 and diabetes type 2. Amongst all, the diabetes type 1 segment is estimated to hold the highest market share during the forecast period.
  • By Patient, the market is classified as adult, geriatric, and paediatric. Amongst all, the adult segment is estimated to hold the highest market share during the forecast period.
  • By Geography, North America is projected to lead the market.

Recent Developments

  • Mankind Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd inked a sub-licensing agreement to co-market anti-diabetes drug remogliflozin etabonate in India. – 23rd December 2019
  • Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone Lispro Formulation Containing – 25th January 2021

Company Profiles

Some of the companies covered in this report are

  • Sanofi-Aventis
  • Eli Lilly
  • Oramed Pharmaceuticals
  • Takeda Pharmaceuticals
  • Boehringer Ingelheim
  • Merck & Co. Inc.
  • Novo Nordisk

Key Topics Covered:

1 Report Description

1.1 Study Objectives

1.2 Market Definition

1.3 Currency

1.4 Years Considered

1.5 Language

1.6 Key Shareholders

2 Research Methodology

2.1 Research Process

2.2 Data Collection and Validation

2.3 Market Size Estimation

2.4 Assumptions of the Study

2.5 Limitations of the Study

3 Executive Summary

3.1 Introduction

3.2 Market Size and Segmentation

3.3 Market Outlook

4 Market Influencers

4.1 Drivers

4.1.1 Sedentary Lifestyle of People and Irregular Dietary Habits

4.1.2 Growing Awareness Amongst People of Antidiabetics Drugs

4.1.3 Government Initiatives in Healthcare Sector

4.2 Restraints

4.2.1 Excessive Cost of Insulin

4.3 Opportunities

4.3.1 New Innovation in Medical Devices Relate to Diabetics

4.3.2 Increased Investment in R&D

4.4 Challenges

4.4.1 Safety Concerns Relating to Some Diabetic Drugs

4.5 Trends

5 Market Analysis

5.1 Regulatory Scenario

5.2 Porter’s Five Forces Analysis

5.3 Impact of COVID-19

5.4 Ansoff Matrix Analysis

6 Global Antidiabetic Drug Market, By Drug Type

6.1 Introduction

6.2 A-Glucosidase Inhibitors (Acarbose)

6.3 Biguanides (Metformin)

6.4 Dipeptidyl Peptidase IV (DPP-IV) Inhibitors (Sitagliptin)

6.5 Meglitinides (Repaglinide)

6.6 Sulfonylureas (Glimepiride)

6.7 Thiazolidinediones (Pioglitazone)

6.8 Others

7 Global Antidiabetic Drug Market, By Diabetes Type

7.1 Introduction

7.2 Diabetes Type 1

7.3 Diabetes Type 2

8 Global Antidiabetic Drug Market, By Patient

8.1 Introduction

8.2 Adult

8.3 Geriatric

8.4 Paediatric

9 Global Antidiabetic Drug Market, By Geography

9.1 Introduction

10 Competitive Landscape

10.1 Competitive Quadrant

10.2 Market Share Analysis

10.3 Strategic Initiatives

11 Company Profiles

  • Abbott Laboratories
  • Aristo Pharmaceuticals Pvt. Ltd
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Biocon Limited C.H.
  • Boehringer Sohn AG & Co.
  • KG Cadila Pharmaceuticals Limited
  • Cipla, Inc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd
  • Halozyme Therapeutics, Inc
  • Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
  • Mankind Pharma Ltd
  • Merck KGaA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc
  • Pfizer Inc
  • PHC Corporation
  • Sanofi S.A
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Tonghua Dongbao Pharmaceutical Co, Ltd
  • Wockhardt Limited

For more information about this report visit https://www.researchandmarkets.com/r/p21f6d

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900